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Abstract 
Background.  Guidelines recommend 10 day treatment courses for acute sore throat but shorter courses may be used in 
practice.  
Aim. To determine whether antibiotic duration predicts adverse outcome of acute sore throat in adults in routine care.   
Design and setting A secondary analysis of a prospective cohort study of 14610 adults presenting with acute sore throat in 
primary care. 
 
Methods. A brief clinical proforma was used to collect symptom severity and examination findings at presentation. 
Outcomes were collected by notes review and in a sample a symptom diary. 
Primary outcome: Re-consultation with new/non-resolving symptoms within 1 month.  Secondary outcome ‘global’ poorer 
symptom control (longer than the median duration or higher than median severity). 
Results.  Antibiotics were prescribed for 60% (8572/14610) of participants. The most commonly prescribed antibiotic 
was phenoxymethylpenicillin (76%, 5656/7474) and prescription durations were largely for 5 (20%), 7 (57%), or 10 
(22%) days.. Compared with 5 day courses those receiving longer courses were less likely to re-consult with new or 
non- resolving symptoms (5 days 15.3%, 7 days 13.9%, 10 days 12.2%, 7 day course adjusted risk ratio 0·92 (0·76, 
1·11) and 10 days 0·86 (0·59, 1·23)) but these differences did not reach statistical significance.  
Conclusions. In adults prescribed antibiotics for sore throat, we cannot rule out a small advantage in terms of reduced re-
consultation for a 10 day course of penicillin but the effect is likely to be small. 
 
Funding: The Medical Research Council. 
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Introduction. 
Acute sore throat is a common illness in everyday primary care practice and most patients are still prescribed 
antibiotics.1-3 Current UK guidelines recommend a ‘no’ or ‘delayed’ prescribing approach4 but when antibiotics are 
indicated then guidelines recommend ten days of penicillin in order to reduce the risk of relapse (PHE5, 
ESCMID6,SIGN7, IDSA8).This recommendation for long antibiotic courses first appeared in the 1950s at a time when 
streptococcal complications were common and based on observing the eradication of streptococci in asymptomatic 
carriers,9.10-13. However, this evidence may not be directly applicable to modern care in more economically developed 
countries for a number of reasons: streptococcal disease has changed over time; studies were largely in children;10-13 
used low doses of penicillin;10 were restricted to those with proven streptococcal infection; 10,11 used stringent 
assessments of compliance;12 and used bacteriological rather than clinical cure.10,11 Only one study found a significant 
increase in recurrent symptoms after a shorter antibiotic course.12 In a study in adults comparing placebo with three 
and seven days of antibiotic treatment, seven days gave superior symptom control and bacteriological eradication 
rates. Recurrent sore throats were most frequent in the 3 day group but there was no difference in re-attendance rates 
between the groups.14 A Cochrane review of longer penicillin courses vs short courses of other antibiotic classes in 
children found superior symptomatic benefit with short courses with comparable other outcomes.15 There are potential 
harms arising from greater exposure to courses of penicillin which is linked to subsequent carriage of resistant 
pneumococci16 and carriage of resistant commensal organisms.17 Not all guidelines recommend such prolonged 
treatment, the Dutch guidelines recommend seven day treatment and no longer recommends ten days for eradication of 
bacteria,19 So if shorter courses lead to effective symptom relief without an increase in recurrence it should be possible 
to significantly reduce the volume of antibiotics prescribed.  
 
Systematic reviews and randomised trials of antibiotics for acute sore throat have found only a modest effect on 
symptoms.21 However, prescribing antibiotics may still be indicated in some instances.21 It is important not to deny the 
benefit of antibiotics to patients at significant risk of severe illness or complications. We need evidence about 
appropriate duration of the antibiotic treatment for acute sore throat in adults in the modern era.  
 
We therefore aimed to describe current antibiotic prescribing for sore throat in UK practice and to investigate whether 
duration of treatment or class of antibiotic was associated with adverse symptomatic outcome or increased re-consultation 
during the subsequent month using a large observational cohort which had been recruited to investigate potential 
prediction of septic complications of acute sore throat22. 
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Methods.  
 
Overall study design. 
As previously reported22,23, the study used a simple one page paper/web based case report form (CRF) documenting 
clinical features to facilitate assembly of a large prospective cohort of patients presenting with acute sore throat. The 
nested studies were two consecutive diagnostic cohorts (n=1107) to develop and validate a clinical score to predict 
bacterial infection25 and a randomised trial (n=1781) which compared the use of the clinical score and the targeted use of a 
rapid antigen detection test with delayed antibiotic prescribing.27 Trial participants were not included in the present 
analysis because their treatment had been allocated according to the trial protocol. Initial recruitment was among six local 
Networks (based in Southampton, Bristol, Birmingham Oxford, Cardiff, Exeter) but was extended nationally during the 
last 18 months of recruitment. 
 
Patient inclusion criteria. Previously well subjects aged 16 years and over, presenting with acute  (14 days or less) sore 
throat as the main symptom, with an abnormal examination of the pharynx (identical criteria to our previous studies).28  
Exclusion criteria were severe mental health problems (e.g. cognitive impairment and unable to consent or assess history) 
and known immune suppression. 
 
Baseline clinical proforma. Age, gender, current smoking status, prior duration of illness and the presence and 
severity of baseline symptoms (sore throat, difficulty swallowing, fever during the illness, runny nose, cough, feeling 
unwell, diarrhoea, vomiting, abdominal pain, headache, muscles ache, sleep disturbance, earache) were documented 
on the CRF. Symptoms were recorded using 4 point Likert scales (none, a slight problem, a moderately bad problem, a 
severe problem), and the presence of signs (pus, nodes, cervical nodes, temperature, fetor, palatal oedema, difficulty 
speaking due to sore throat).  The recruiting physician recorded antibiotic type and duration in the CRF. 
 
Progression/non resolution of illness   This was defined as re-consultation with non-resolving symptoms or 
development of a new respiratory diagnosis/symptom/sign within a month of the index presentation - similar to 
outcomes used previously in a trial of antibiotics for lower respiratory infection in adults29 and in a cohort of children 
and ascertained using notes review.30  Practice staff collected this outcome retrospectively and research staff who were 
not blinded to the treatment used and is available for the whole cohort. 
 
Documentation of symptomatic outcome 
A symptom diary was randomly allocated to a proportion of those recruited to the study to achieve the pre-specified 
target of 1800 diaries. The diary was similar to that used in other studies. 28,31 Patients completed the diary each night 
until symptoms resolved or up to 14 nights.  Each symptom sore throat, difficulty swallowing, feeling unwell, fevers, 
sleep disturbance was scored (0=no problem to 6=as bad as it could be): Symptomatic outcomes were only available 
for those returning diaries. 
.  
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Sample size. Sample size calculations for the main study were based on the prediction of complications- a rare 
outcome. For the proposed analysis of diary data a sample of 1800 patients allowing for 20% loss to follow-up of 
diaries (900 of whom would not be expected to have antibiotics), would have power to detect variables with 
prevalences of 20% to 80% with an odds ratio of 2 for adverse symptomatic outcome among the no antibiotic group. 
Adverse symptomatic outcome was defined as severe symptoms or prolonged symptoms.  
 
Outcomes   
Primary outcome: Re-consultation with progression or non-resolution of illness within one month of the index 
consultation. 
Secondary outcomes:  Only determined in those with diary data, worse symptomatic outcomes (above median for 
either duration or severity of illness, duration of moderately bad symptoms, symptom severity on day 2-4, worsening 
of illness)  
All outcomes reported in relation to prescribed antibiotic duration.  
 
Analysis.  All analyses were based on reported treatment at the index consultation. The subgroup analyses reported in 
this paper were specified in advance. Duration of symptoms was analysed using Cox regression, linear regression was 
used for symptom severity and generalised linear regression model with a log link for re-consultation and adverse 
symptomatic outcome. We have reported both the univariate statistics as well as the relationships after controlling for 
the severity of all baseline symptoms, antibiotic type (immediate or delayed) and clustering of patients by practice. To 
control for potential confounding by indication, we calculated a propensity score based on predictors of antibiotic 
prescribing. The propensity score was calculated based on variables which were significant predictors (p<0.05) of 
antibiotic prescribing strategy (5 days/7 days/10 days) in a multinomial logit model (mlogit in Stata) and was then 
included as an additional covariate in the prior models. This method was chosen in preference to propensity score 
matching since the outcome measure is categorical and therefore the analysis is more complex than for binary logistic 
models where propensity score matching might make sense32. The predicted probability from this model was then used 
as the propensity score in the analysis of the relationship between prescribing strategy and the study outcome 
measures. In order to explore whether those with higher probability of streptococcal infection experienced differential 
benefit from antibiotics we used the Centor score and the FeverPAIN score. The Centor score derived in hospital 
outpatients is used to predict the probability of Streptococcal infection, has been shown to be related to response to 
antibiotics and is widely used internationally.33,34 The FeverPAIN score may also be used to predict the probability of 
streptococcal infection (A,C&G)  in community samples and has been shown to be highly predictive of time to 
symptom resolution and symptom severity.25 The FeverPAIN score comprises fever in the past 24 hours, purulence, 
rapid attendance (within three days), inflamed tonsils and no cough or cold symptoms. We tested for an interaction 
between Centor/FeverPAIN and symptom severity. We also used the Centor/FeverPAIN score to dicotomise the 
sample into those more or less likely to have a streptococcal infection, we used the cut point of 3 and above for Centor 
which is widely used to direct antibiotic prescribing and for FeverPAIN 0-2 vs 3 and over. For Centor the probability 
of a streptococcus swab positive result is 15% for those with a score of 2 and 32% for those with a score of 3 or 
above33, for FeverPAIN risk of positive streptococcal swab is 26%  for those with a score of 0 1 or 2 and for a score of 
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3 and above it is 60%.25 Results are presented both for complete cases and for models with significant predictors of the 
propensity score imputed using a chained equations multiple imputation model. Outcome measures were not imputed 
as it was not possible to distinguish between individuals who were missing data because they did not complete a diary 
when asked and those who were not asked to complete one. 
Analyses were carried out in Stata version 12.1.   
 
Results. 
14610 adult patients were recruited between 10th November 2006 and the 1st June 2009 from 616 general practices. 
1629/2876 (57%) of those requested returned the symptom diary. There were no substantial differences in baseline 
characteristics between those returning the symptom diary and the main sample (Ref delayed paper). The inter-rater 
reliability for assessing return with non-resolution of symptoms was good (kappa 0.84).24 Those receiving shorter 
courses of antibiotics were less likely to have a history of fever in the past 24 hours and less likely to have severely 
inflamed tonsils or pus on the tonsils (Table 1) and hence a lower Centor and FeverPAIN score.  Those receiving 
antibiotics other than penicillin also had less severe symptoms (Appendix Table 1). Those given immediate antibiotics 
had more severe symptoms at baseline and were more likely to have a history of fever and severe inflammation or pus 
on tonsils (ref delayed paper).  
Table 1 
 
Immediate antibiotics were prescribed for 6088/14610 (42%) and delayed antibiotics for 2484/14610 (18 %). The most 
commonly prescribed antibiotic was phenoxymethylpenicillin (76% 5656/7474) and the majority of these prescriptions 
were for three durations; 5 (20%), 7 (57%), or 10 (22%) days. The proportions of antibiotic class and duration in those 
returning a diary were not different from the main sample (Appendix Table 2), From the diary data of those reporting 
taking the antibiotics (n=956); those prescribed a course of 10 days reported taking antibiotics for 9·33 days (s.d.1·73); 
those prescribed a course of 7 days reported taking antibiotics for 7·01 days (SD 2·14) and those prescribed a course 
of 5 days reported taking them for 5·75 days (SD 2·04). 
Table 2 
 
When adjusting for propensity to prescribe antibiotics, those prescribed longer courses of antibiotics re-consulted less 
often during the month following the index consultation compared to those prescribed a 5 day prescription. However, 
this difference was not statistically significant (7 days: RR 0·92 (95% CI 0·76, 1·11; p=0·377); 10 days: RR 0·86 
(0·59, 1·23; p=0·408). Similar results were observed when adjusting for baseline severity and controlling for 
clustering of patients by practice (Table 2). Antibiotics other than penicillin were associated with a significantly 
greater risk of re-consultation (Table 2).   
 
 
 
When controlling for propensity to prescribe or baseline severity and using five day prescription as comparator (Table 
3), outcomes were similar in those prescribed seven days antibiotics. In those prescribed antibiotics for ten days, 
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adverse symptomatic outcomes were similar when controlling for baseline differences 1·13 (0·95, 1·35; p=0.·162) but 
were slightly worse when adjusting for propensity to prescribe 1·22 (1·02, 1·46; p=0·026) Those prescribed 
phenoxymethylpenicillin experienced similar symptomatic outcomes compared to those receiving antibiotics other 
than penicillin (Table 3).  
 
Table 3 
When tested independently neither the severity of symptoms on day 2-4 nor the duration of moderately bad symptoms 
was related to duration of prescription issued nor the class of antibiotic prescribed (Table 4 and Table 5 Figure 1).   
 
Table 4 
 
Table 5 
 
Figure 1 Proportion experiencing symptoms rated moderately bad or worse according to duration of prescribed 
antibiotics 
 
 
 
 
 
With the exception of the mean symptom severity score there was no evidence of an interaction between FeverPAIN 
score and outcomes related to the duration of antibiotic prescription.  There was no evidence of any interaction 
between FeverPAIN score and outcomes related to antibiotic type.  (Appendix Tables 3 and 4) 
There was no evidence of any interaction between Centor score and outcomes related to the duration of antibiotic 
prescription nor on outcomes related to antibiotic type (Appendix tables 5 and 6) 
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Discussion. 
 
Summary 
 
This large observational cohort of patients enabled us to explore the effect of prescribing antibiotics in routine practice on 
re-consultation and symptom resolution. Although a seven day course is most often prescribed, five and ten day courses 
each accounted for approximately one fifth of prescriptions. Compared with a five day course those prescribed a ten day 
course appeared to have slightly worse global symptomatic outcome (longer than the median duration or higher than 
median severity) after adjustment for propensity to prescribe, the re-consultation rate was higher with shorter courses but 
this difference did not reach statistical significance. Current guidelines recommending penicillin treatment for ten days are 
not supported by these findings where the purpose is to provide symptom relief rather than bacterial eradication. 
There is no evidence that phenoxymethylpenicillin is inferior to other antibiotic classes for symptom control, and given 
low rates of penicillin non-susceptibility of typical bacterial pathogens, it should be the first choice antibiotic. The 
implications for symptomatic benefit and re-consultation are similar for those predicted to be more or less likely to have a 
streptococcal throat infection using symptom scores. 
 
Strengths and limitations 
The study was designed using a simple template to minimise selection bias and thus to produce a large generaliseable 
prospective cohort. Recruitment of patients with acute illness is constrained by time issues and in common with other 
studies of acute infection35-37 documentation of those not approached was poor (since time pressure to recruit also meant 
time pressure to document non recruitment).  The large sample prospectively recruited in routine practice with the 
inclusion of diary data enabled the study of different antibiotic classes and duration of prescription both on re-consultation 
and on symptomatic outcomes, which is likely to reflect the real life experience of patients. As previously reported (ref 
delayed paper ) there is evidence of a greater propensity to prescribe for those with more severe symptoms at baseline and 
a longer duration of antibiotics was also more likely in those with more severe symptoms. We have adjusted for propensity 
to prescribe and for baseline severity of symptoms in our analysis but cannot rule out residual confounding. Those who 
completed and returned the symptom diary may represent a more adherent population more generally so estimates of 
medication adherence may be inflated compared to the general population.  The assessors of re-consultation were not 
blinded to the treatment allocation, which would have been available in the clinical record, since the primary aim of the 
cohort was to assess risk factors for septic complications we think it unlikely this would introduce any bias in recording of 
re-consultation. The reported duration of antibiotic consumption in those prescribed five days appears longer than that 
dispensed but this is an artefact as each day antibiotics were taken were included and hence the average reflects the final 
doses being on day six. Those prescribed antibiotics other than penicillin experience similar symptomatic outcomes but 
were at greater risk of re-consultation, this may reflect factors not controlled for in the analysis which determined the 
antibiotic choice. In recent years Fusobacterium necrophorum has emerged as a relevant pathogen in recurrent and severe 
sore throat, 38although it may be isolated from 10% of  community samples39 and may be rarely associated with severe 
infection its precise contribution to acute uncomplicated sore throat illness is hard to ascertain. The analysis adjusted for 
propensity to prescribe and the negative interaction terms for Centor and FeverPAIN suggest that the adjustment took 
account of streptococcal infection (that there was no evidence of differential outcomes in those more likely to have 
streptococcal infection after adjustment) however these scores will not account for F. necrophorum and hence we can not 
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rule out residual confounding and this may account for the small difference in re-attendance (5 days 15.3% 10 days 
12.2%).  It is of note however that the use of broad spectrum antibiotics was not associated with improved outcomes. 
Whilst the results fail to show superiority of longer courses of penicillin for symptom relief or re-consultation this is not 
the same as equivalence and may reflect a lack of power. 
 
Comparison with existing literature 
The most commonly prescribed antibiotic was phenoxymethylpenicillin but there was variation in the duration of the 
prescription, with the majority receiving seven days (52%) – an observation which is at odds with the recommendations of 
current guidelines.5 Although prescribing rates are similar, broad spectrum antibiotic prescribing is higher in the US (86% 
antibiotics other than penicillin or erythromycin.20) The prescription of five or seven day duration antibiotics did not appear 
to confer any significant increase in re-consultation in the month following the index consultation nor any worse 
symptomatic outcomes. A systematic review of studies in children found no difference in clinical outcomes after shorter 
courses of antibiotics but the comparison groups were ten days of penicillin compared with shorter courses of other 
antibiotic classes15 and so is not directly comparable. There is a paucity of trial data in adults but one trial identified 
showed superiority of seven over three days treatment with penicillin.14 
We examined the effect of antibiotics other than penicillin and did not find convincing evidence of differential 
symptomatic outcome. Non- penicillin antibiotics were associated with higher re-consultation rates. In a Cochrane review 
of antibiotic type in acute sore throat, no differences in symptom resolution were observed but clinical relapse was less 
likely following cephalosporin treatment.40  
Implications.  
 
When antibiotics are indicated current guidelines recommend a ten day course. We found a ten day course of antibiotics 
was not associated with greater benefit on either risk of re-consultation or symptom control compared to five or seven days 
antibiotic duration. In situations where bacterial eradication is not specifically needed and where symptomatic cure is the 
goal, if a decision to prescribe is made then a shorter course of penicillin may be sufficient and this finding should be 
confirmed with a randomised controlled trial.  These finding should not be generalised to areas with a higher incidence of 
acute rheumatic fever. 
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Table 1 Baseline characteristics by duration of antibiotic prescription in the whole cohort 
 5 days 7 days 10 days 
Baseline clinical assessment    
Mean severity of sore 
throat/difficulty swallowing on a 4 
point Likert scale (SD) 
3·27 (0·65) 3·26 (0·67)  3·18 (0·63) 
Mean severity of all baseline 
symptoms on a 4 point Likert 
scale (SD) 
2·18 (0·40)  2·15 (0·40)  2·12 (0·41)  
Mean FeverPain score* 1·72 (1·30)  1·94 (1·32)  2·36 (1·18)  
Mean Centor score 1.85 (1.09)  2.06 (1.10)  2.33 (1.01) 
Prior duration in days (SD) 4·61 (3·57)  4·68 (4·22)  4·11 (3·36) 
Age in years (SD) 33·16 (14·05)  33·88 (14·21)  32·35 (13·75)  
Female gender 984/1466 (67·1%) 2832/4187 (67·6%) 1102/1632 (67·5%) 
Smoker 356/1464 (24.3%) 966/4168 (23·2%) 285/1621 (17·6%) 
Fever in last 24 hours 962/1458 (66·0%) 2816/4171 (67·5%) 1152/1630 (70·7%) 
Temperature oC (SD) 36·86 (0·72)  36·93 (0·72)  36 ·99 (0·68)  
Pus on tonsils 648/1460 (44·4%) 2131/4170 (51·1%) 1050/1627 (64·5%) 
Severely inflamed tonsils 209/1371 (15·2%) 816/3945 (20·7%) 325/1546 (21·0%) 
Number of prior medical problems 
 
0·27 (0·52)  0·25 (0·52)  0·23 (0·49)  
Return within 4 weeks with new 
or worsening symptoms 
222/1449 (15·3%) 577/4135 (13·9%) 198/1620 (12·2%) 
Return within 4 weeks with 
complications  
 
13/1449 (0·9%) 55/4135 (1·3%) 22/1620 (1·3%) 
 FeverPAIN score comprises fever in the past 24 hours, purulence, rapid (within three days) attendance, inflamed tonsils and no cough or cold symptoms  Centor score comprises a history of fever, pus on tonsils, enlarged glands and absence of cough 
 
Table 2 Re-consultation with new or worsening symptoms in the month following the index consultation according to 
duration of antibiotic prescribed and antibiotic class 
 
Reported new or 
worsening 
symptoms 
Univariate risks 
ratio (95% CI; p-
value) 
Risk ratio 
controlling for 
baseline severity, 
and clustering 
(95% CI, p-value) 
Risk ratio 
controlling for 
propensity score 
Risk ratio 
controlling for 
propensity score 
in the imputed 
dataset 
Duration of antibiotic 
prescription 
     
5 days  
(reference category) 
222/1449 (15·3%) 1·00 1·00 1·00 1·00 
7 days 577/4135 (13·9%) 0·91  
(0·75, 1·05) 
p=0·201  
0·93  
(0·78, 1·08) 
p=0·321|    
  
0·92  
(0·76, 1·11) 
p=0·377 
0·92  
(0·76, 1·10) 
p=0·360 
10 days 198/1620 (12·2%) 0·80  
(0·67, 0·95) 
p=0·013  
0·81  
(0·55, 1·19) 
p=0·287  
0·86  
(0·59, 1·23) 
p=0·408  
0·85  
(0·59, 1·23) 
p=0·395  
Antibiotic class      
Phenoxymethylpenicillin 
(reference category) 
725/5,624 (12·9%) 1·00 1·00 1·00 1·00 
Other antibiotics 302/1847 (16·3%) 1.27  
(1.12, 1.44) 
p<0.001 
1.28  
(1.11, 1.47) 
p=0.001 
1·27  
(1·11, 1·49) 
p=0·002  
1·26  
(1·09, 1·45) 
p=0·001  
All models controlled for immediate or delayed prescribing and clustering of patients by practice 
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Table 3 Adverse symptomatic outcome (greater than median symptom severity in days 2-4 or greater than median 
duration of symptoms) according to duration of antibiotic prescribed and antibiotic class 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*for duration, the model also controls for whether the antibiotics prescribed were immediate or delayed 
 
Table 4 Symptom severity on day 2-4 according to duration of antibiotic prescribed and antibiotic class 
 
 
Mean symptom 
severity (SD) 
Difference Difference 
controlling for 
clustering and, 
Antibiotic type 
and baseline 
severity score 
(CI) 
Difference controlling 
for propensity score 
Difference controlling 
for propensity score in 
the imputed dataset 
Duration of antibiotic 
prescription 
     
5 days (reference 
category) 
2·00 (1·22)      
7 days 1·99 (1·21)  -0·01 (-0·22, 
0·19; p=0·896)  
0·01 (-0·18, 0·19; 
p=0.935) 
0·06 (-0·13, 0·25; 
p=0·520)  
 0·05 (-0·14, 0·24; 
p=0·587) 
10 days 2·10 (1·20)  0·10 (-0·15, 0·35; 
p=0·426)  
0·13 (-0·14, 0·41; 
p=0·330)  
 0·21 (-0·06, 0·48, 
p=0·119)  
0·20 (-0·06, 0·48; 
p=0·130)  
Antibiotic class      
Phenoxymethylpenicillin 
(reference category) 
2·01 (1·22)     
Other antibiotics 2·02 (1·15)  0·01 (-0·17, 0·20; 
p=0·897)  
0·02 (-0·17, 0·21; 
p=0·826) 
0·00 (-0·20, 0·19; 
p=0·965)  
-0·02 (-0·21, 0·16; 
p=0·796)  
 
  
 
Poor symptomatic 
outcome 
Univariate risk 
ratio (95% CI; p-
value) 
Risk ratio 
controlling for 
baseline severity, 
Antibiotic type 
(immediate or 
delayed) and 
clustering (95% 
CI, p-value)* 
Risk ratio 
controlling for 
propensity score 
Risk ratio 
controlling for 
propensity score in 
imputed dataset 
 
Duration of antibiotic 
prescription 
     
5 days (reference category) 105/185 (56·8%) 1·00 1·00 1·00  
7 days 312/535 (58·3%) 1·03  
(0·89, 1·19) 
p=0·713  
1·03  
(0·89, 1·20)  
p=0·685  
1·06  
(0·91, 1·23) 
p=0·443  
1·06  
(0·91, 1·23) 
p=0·462) 
10 days 108/168 (64·3%) 1·13  
(0·96, 1·34) 
 p=0·148 
1·13  
(0·95, 1·35) 
 p=0·162  
1·22 
(1·02, 1·46)  
p=0·026  
1·22  
(1·02, 1·46)  
p=0·026  
Antibiotic class      
Phenoxymethylpenicillin 
(reference category) 
419/ 714 (58·7%) 1·00 1·00 1·00 1·00 
Other antibiotics 125/206 (60·7%) 1·03  
(0·91, 1·17) 
p=0·603  
1·04  
(0·91, 1·18) 
p=0·547 
0·98 
(0·84, 1·12) 
p=0·807  
0·94  
(0·68, 1·32) 
p=0·733 
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Table 5 Duration of moderately bad symptoms according to duration of antibiotic prescribed and antibiotic class  
 
Duration of 
moderately bad 
symptoms: median 
days (IQR) 
Univariate 
Risk ratio 
Hazard ratio 
controlling for 
clustering, 
Antibiotic type 
(immediate or 
delayed) and 
baseline severity 
score (CI; p-value) 
Hazard ratio 
controlling for 
propensity score 
Hazard ratio 
controlling for 
propensity score in 
imputed dataset 
Duration of antibiotic 
prescription 
     
5 days  
(reference category) 
3 (2,5) 1·00 1·00 1·00 1,00 
7 days 3 (2,5) 1·06  
(0·89, 1·27) 
p=0·527  
1·05  
(0·91, 1·23) 
 p=0·488 
1·05 
(0·90, 1·23) 
 p=0·513  
1·07 
(0·91, 1·25) 
p=0·418  
10 days 3 (2,5) 0·99  
(0·79, 1·24) 
p=0·957 
0·99  
(0·83, 1·20) 
 p=0·963)  
0·92  
(0·74, 1·14) 
 p=0·432  
0·92  
(0·73, 1·15) 
 p=0·460  
Antibiotic class      
Phenoxymethylpenicillin 
(reference category) 
3 (2,5) 1·00 1·00 1·00 1·00 
Other antibiotics 3 (2,5) 0·94  
(0·80, 1·10)  
p=0·435 
0·94  
(0·82, 1·07) 
 p=0·350  
1·03  
(0·88, 1·21)  
p=0·698 
1·04  
(0·89, 1·21) 
 p=0·631  
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How this fits in:  Antibiotics are not usually indicated for acute sore throat  When streptococcal infection is probable or the risk of complications high, antibiotics are indicated and a ten 
day course is usually recommended  We found evidence that a shorter duration of antibiotic prescription (five days) is associated with similar 
symptomatic outcomes and without increased risk of re-consultation when compared with longer courses of 
antibiotic  These findings should be confirmed with a randomised controlled trial since exposure to antibiotics could be 
potentially reduced if confirmed. 
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Appendix Table 1 
Baseline characteristics by Antibiotic type 
 Phenoxymethylpenicillin 
N=5696 
Other 
N=1857 
Clinical assessment   
Mean severity of sore throat/difficulty 
swallowing on a 4 point Likert scale 
(SD) 
3·28 (0·64)  3·13 (0·70)  
Mean severity of all baseline 
symptoms* on a 4 point Likert scale 
(SD) 
2·15 (0·40)  2·14 (0·40)  
Mean FeverPain score 2·12 (1·28)  1·57 (1·28)  
Mean Centor Score 2.45 (0.97)  1.97 (1.05)  
Prior duration in days (SD) 4·36 (3·60)  5·14 (4·94) 
Age in years (SD) 32·25 (13·60)  37·01 (14·95)  
Female  3,835/5696 (67·3%) 1,265/1,857 (68·1%) 
Smoker 1,296/5663 (22·9%)  384/1850 (20·8%) 
Fever in last 24 hours 3897/5672 (68·7%)  1,213/1841 (65·9%) 
Temperature oC (SD) 36·95 (0·71)  36·87 (0·73)  
Pus on tonsils 3,225/5,668 (56·9%)       718/1841 (39·0%) 
Severely inflamed tonsils 1,153/ 5,338 (21·6%)        234/1736 (13·5%) 
Number of prior medical problems 
 
0·23 (0·49)  0·31 (0·59)  
Return within 4 weeks with new or 
worsening symptoms 
725/ 5,624 (12·9%)  302/1,847 (16·3%) 
Return within 4 weeks with 
complications  
 
65/5,624 (1·2%)     28/1847 (1·5%) 
 
 
 
 
Appendix Table 2 Type and duration of antibiotics issued comparison of those completing symptom diary with full cohort. 
 
 Total cohort 
N=7474 
Patients who completed diaries 
N=922 (i) 
 
 
Given antibiotics Delayed antibiotics Given antibiotics Delayed antibiotics 
Antibiotic type     
Phenoxymethylpenicillin 4354/5793 (75·2%) 1302/1681 (77·4%) 552 /725 (76·1%) 163/197 (82·7%) 
Amoxicillin 601/5793 (10·4%) 165/1681 (9·8%) 78/725 (10·8%) 17/197 (8·6%) 
Erythromycin 542/5793 (9·4%) 171/1681 (10·2%) 56/725 (7·7%) 11/197 (5·6%) 
Other (ii) 296/5793 (5·1%) 43/1681 (2·6%) 39/725 (5·4%) 6/197 (3·0%) 
Duration of course     
5 days 1,125/5,651 (19·9%)    327/1,631 (20·0%) 147/709 (20·7%) 36/191 (18·8%) 
7 days 3222/5,651 (57·0%)     919/1,631 (56·3%) 427/709 (60·2%) 109/191 (57·1%) 
10 days 1,249/5,651 (22·1%) 371/1,631 (22·7%) 127/709 (17·9%) 42/191 (22·0%) 
Other duration 56/5651 (1·0%) 14/1631 (0·9%) 8/709 (1·1%) 4/191 (2·1%) 
Took antibiotics (iii)   670/692 (96·8%) 115/191 (60·2%) 
Mean number of days for 
which antibiotics were taken 
  7·07 (2.22)  7·12 (2.92)  
(i) 922/1512 completed diaries and also prescribed antibiotics 
(ii) Included cephalexin (191) co-amoxiclav (40) clarithromycin (38) and doxycycline (22) 
(iii) There were an additional 105 people out of 554 (18·8%) who were not prescribed antibiotics who reported taking 
them. 
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Appendix Table 3 
Effect of duration of antibiotic prescribing among those more likely to have streptococcal infection (FeverPAIN 3 or above) on 
poor symptomatic outcome, re-consultation, duration of symptoms and symptom severity. 
 
  Interaction 
term 
Univariate risk 
ratio (95% CI; p-
value) 
Risk ratio 
controlling for 
baseline severity 
and clustering 
(95% CI, p-value)* 
Risk ratio 
controlling for 
propensity score 
Risk ratio 
controlling for 
propensity score 
in imputed 
dataset 
 Poor symptomatic 
outcome  
     
5 days 26/48 (54·2%)  1·00 1·00 1·00 1·00 
7 days 86/282 (47·5%) 0.92 (0.82, 
1.04; p=0.179)  
0·88 (0·65, 1·19; 
p=0·395)  
0·88 (0·65, 1·19; 
p=0·413)  
0·93 (0·68, 1·27; 
p=0·652)  
0·93 (0·68, 1·27; 
p=0·637) 
10 days 48/72 (66·7%) 1.02 (0.91, 
1.15; p=0.680)  
1·23 (0·91, 1·67; 
p=0·185)  
1·24 (0·94, 1·65; 
p=0·127)  
1·29 (0·96, 1·74; 
p=0·088)  
1·29 (0·96, 1·74; 
p=0·089)  
 Re-consultation       
5 days 56/353 (15·9%)  1·00 1·00 1·00 1·00 
7 days 177/1295 (13·7%) 0.98 (0.88, 
1.09; p=0.657)  
0·86 (0·65, 1·14; 
p=0·291)  
0·85 (0·64, 1·164 
p=0·273)  
0·84 (0·63, 1·12; 
p=0·228)  
0·85 (0·64, 1·12; 
p=0·243) 
10 days 97/712 (13·6%) 1.03 (0.92, 
1.16; p=0.609)  
0·86 (0·63, 1·16; 
p=0·325)  
0·89 (0·57, 1·38; 
p=0·609)  
0·85 (0·56, 1·28; 
p=0·430)  
0·85 (0·56, 1·28; 
p=0·434)  
 Duration of symptoms       
5 days 3 (2,5)  1·00 1·00 1·00 1·00 
7 days 3 (2,4) 1·06 (0·94, 
1·19; p=0·378) 
1·16 (0·82, 1·63; 
p=0·412)  
1·14 (0·84, 1·56; 
p=0·403)  
1·20 (0·87, 1·65; 
p=0·270)  
1·20 (0·87, 1·66; 
p=0·262) 
10 days 3 (2,5) 0.93 (0.81, 
1.07; p=0.326)  
0·84 (0·56, 1·25; 
p=0·385)  
0·85 (0·61, 1·19; 
p=0·345)  
0·90 (0·63, 1·27; 
p=0·539)  
0·89 (0·63, 1·27; 
p=0·527)  
 Mean symptom 
severity score  
 Difference Difference 
controlling for 
clustering and, 
Antibiotic type and 
baseline severity 
score (CI) 
Difference 
controlling for 
propensity score 
Difference 
controlling for 
propensity score 
in the imputed 
dataset 
5 days 1·83 (1·18)       
7 days 1·85 (1.22)  0.01 (-0.12, 
0.13; p=0.959)  
0·02 (-0·37, 0·42; 
p=0·910)  
0·04 (-0·29, 0·37; 
p=0·807)  
0·09 (-0·26, 0·43; 
p=0·626)  
0·08 (-0·27, 0·42; 
p=0·664) 
10 days 2·31 (1·32)  0.18 (0.03, 
0.33; p=0.018)  
0·48 (0·03, 0·94; 
p=0·038)  
0·48 (0·08, 0·88; 
p=0·018)  
0·51 (0·10, 0·92; 
p=0·015)  
0·51 (0·11, 0·92; 
p=0·013) 
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Appendix Table 4 
Effect of antibiotic type among those more likely to have streptococcal infection (FeverPAIN 3 or above) on poor symptomatic 
outcomes, re-consultation, duration of symptoms and symptom severity  (penicillin vs other) 
 
  Interaction 
term (95% 
CI; p-value) 
Univariate risk 
ratio (95% CI; 
p-value) 
Risk ratio 
controlling for 
baseline severity 
and clustering 
(95% CI, p-
value)* 
Risk ratio 
controlling for 
propensity score 
Risk ratio 
controlling for 
propensity score 
in imputed 
dataset 
 Poor symptomatic 
outcome 
     
Phenoxymethylpenicillin 138/260 (53·1%)  1·00 1·00 1·00 1·00 
Other antibiotics 32/55 (58·2%) 1.04 (0.94, 
1.13; p=0.463)  
1·10 (0·85, 1·41; 
p=0·474)  
1·10 (0·86, 1·39; 
p=0·450)  
1·00 (0·88, 1·13; 
p=0·966)   
1·08 (0·86, 1·35; 
p=0·503)  
 Re-consultation       
Phenoxymethylpenicillin 267/2026 (13·2%)  1·00 1·00 1·00 1·00 
Other antibiotics 67/396 (16·9%) 0·99 (0·74, 
1·32; p=0·944)  
1·28 (1·00, 1·64; 
p=0·046)     
1·28 (0·99, 1·66; 
p0·064)  
1·30 (1·00, 1·69; 
p=0·046)  
1·28 (1·00, 1·64; 
p=0·049)  
 Duration of 
symptoms 
     
Phenoxymethylpenicillin 3 (2,4)  1·00 1·00 1·00 1·00 
Other antibiotics 3 (2,5) 1·05 (0·79 
1·39; p=0.756)  
1·00 (0·74, 1·36; 
p=0·983)  
1·00 (0·79, 1·28; 
p=0·981) 
1·05 (0·84, 1·32; 
p=0·670)  
1·08 (0·86, 1·35; 
p=0·516)  
 
Mean symptom 
severity score 
 Difference Difference 
controlling for 
clustering and, 
Antibiotic type 
and baseline 
severity score (CI) 
Difference 
controlling for 
propensity score 
Difference 
controlling for 
propensity score 
in the imputed 
dataset 
Phenoxymethylpenicillin 1.97 (1·25)      
Other antibiotics 1.93 (1·18)  -0·07 (-0·43, 
0·29; p=0·699)  
-0·04 (-0·40, 
0·32; p=0·838)  
-0·03 (-0·36, 0·31; 
p=0·882)  
-0·10 (-0·45, 
0·26; p=0·589)  
-0·08 (-0·42, 
0·26; p=0·651)  
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Appendix Table 5  
Effect of duration of antibiotic prescribing among those more likely to have streptococcal infection (Centor 3 or above) on poor 
symptomatic outcome, re-consultation, duration of symptoms and symptom severity. 
 
  Interaction term Univariate risk 
ratio (95% CI; 
p-value) 
Risk ratio 
controlling for 
baseline severity 
and clustering 
(95% CI, p-
value)* 
Risk ratio 
controlling for 
propensity score 
Risk ratio 
controlling for 
propensity score 
in imputed 
dataset 
 Poor symptomatic 
outcome  
     
5 days 38/75 (50.7%)  1.00 1.00 1.00 1.00 
7 days 122/242 (50.4%) 0.91 (0.68, 1.22; 
p=0.530) 
0.99 (0.77, 1.29; 
p=0.969)  
0.99 (0.78, 1.25; 
p=0.916)   
1.01 (0.79, 1.29; 
p=0.933)  
1.01 (0.79, 1.29; 
p=0.952)  
10 days 58/88 (65.9%) 1.23 (0.89, 1.70; 
p=0.205)  
1.30 (0.99, 1.70; 
p=0.055)  
1.31 (1.02, 1.66; 
p=0.031)  
1.36 (1.06, 1.73; 
p=0.014)  
1.36 (1.06, 1.73; 
p=0.014)  
 Re-consultation      
5 days 83/535 (15.5%)  1.00 1.00 1.00 1.00 
7 days 260/1834 (14.2%) 1.03 (0.73, 1.45; 
p=0.877)  
0.91 (0.73, 1.15; 
p=0.437)  
0.92 (0.71, 1.21; 
p=0.564)  
0.88 (0.66, 1.16; 
p=0.370)  
0.88 (0.67, 1.16; 
p=0.375) 
10 days 127/945 (13.4%) 1.25 (0.83, 1.88; 
p=0.264) 
0.87 (0.67, 1.12; 
p=0.271)  
0.90 (0.60, 1.34; 
p=0.599)  
0.89 (0.60, 1.32; 
p=0.559) 
0.89 (0.60, 1.31; 
p=0.557)  
 Duration of symptoms      
5 days 3 (2,5)  1.00 1.00 1.00 1.00 
7 days 3 (2,4) 1.15 (0.81, 1.61; 
p=0.440)  
1.12 (0.85, 1.49; 
p=0.421) 
1.13 (0.87, 1.45; 
p=0.354)  
1.16 (0.90, 1.51; 
p=0.253)  
 1.17 (0.90, 1.51; 
p=0.245)  
10 days 3 (2,5) 0.83 (0.57, 1.22; 
p=0.346) 
0.89 (0.64, 1.24; 
p=0.482)  
0.90 (0.67 1.19; 
p=0.449)  
0.89 (0.65, 1.21; 
p=0.452)  
0.89 (0.65, 1.20; 
p=0.441) 
 Mean symptom 
severity score  
 Difference Difference 
controlling for 
clustering and, 
Antibiotic type 
and baseline 
severity score 
(CI) 
Difference 
controlling for 
propensity score 
Difference 
controlling for 
propensity score 
in the imputed 
dataset 
5 days 1.90 (1.25)       
7 days 1.92 (1.29)  0.02 (-0.38, 0.43; 
p=0.908) 
0.02 (-0.30, 0.35; 
p=0.896)  
0.02 (-0.27, 0.31; 
p=0.906)  
0.03 (-0.27, 0.34; 
p=0.823). 
0.03 (-0.27, 0.33; 
p=0.857)  
10 days 2.25 (1,22)  0.42 (-0.05, 0.89; 
p=0.083)  
0.35 (-0.04, 0.74; 
p=0.078)  
0.36 (=0.01, 0.73; 
p=0.053)  
0.38 (0.003, 0.75; 
p=0.048)  
0.38 (0.01, 0.75; 
p=0.046)  
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Appendix Table 6 
Effect of antibiotic type among those more likely to have streptococcal infection (Centor 3 or above) on poor symptomatic 
outcomes, re-consultation, duration of symptoms and symptom severity  (penicillin vs other) 
 
  Interaction term 
(95% CI; p-
value) 
Univariate risk 
ratio (95% CI; p-
value) 
Risk ratio 
controlling for 
baseline severity 
and clustering 
(95% CI, p-
value)* 
Risk ratio 
controlling for 
propensity score 
Risk ratio 
controlling for 
propensity score 
in imputed 
dataset 
 Poor symptomatic 
outcome 
     
Phenoxymethylpenicillin 188/348 (54.0%)  1.00 1.00 1.00 1.00 
Other antibiotics 39/70 (55.7%) 1.00 (0.77, 1.29; 
p=0.995) 
1.03 (0.82, 1.30; 
p=0.793)  
1.04 (0.85, 1.29; 
p=0.690)  
1.01 (0.82, 1.23; 
p=0.955)  
1.02 (0.83, 1.24; 
p=0.873)  
 Re-consultation       
Phenoxymethylpenicillin 382/2835 (13.5%)  1.00 1.00 1.00 1.00 
Other antibiotics 99/573 (17.3%) 0.97 (0.74, 1.28; 
p=0.832)  
1.28 (1.05, 1.57; 
p=0.016)  
1.28 (1.02, 1.61; 
p=0.036)  
1.33 (1.05, 1.68; 
p=0.017)  
1.29 (1.03, 1.62; 
p=0.026)  
 Duration of 
symptoms 
     
Phenoxymethylpenicillin 3 (2,4)  1.00 1.00 1.00 1.00 
Other antibiotics 3 (2,5) 1.03 (0.77, 1.37; 
p=0.843)  
0.99 (0.75, 1.29; 
p=0.916)  
 1.00 (0.80, 1.25; 
p=0.980)   
1.02 (0.81, 1.29; 
p=0.870)  
1.03 (0.82, 1.30; 
p=0.783)  
 Mean symptom 
severity score 
 Difference Difference 
controlling for 
clustering and, 
Antibiotic type 
and baseline 
severity score 
(CI) 
Difference 
controlling for 
propensity score 
Difference 
controlling for 
propensity score 
in the imputed 
dataset 
Phenoxymethylpenicillin 1.00 (1.26)       
Other antibiotics 1.96 (1.26)  -0.11 (-0.46, 
0.24; p=0.538)  
-0.03 (-0.36, 
0.29; p=0.837)  
-0.01 (-0.31, 
0.29; p=0.934)  
-0.06 (-0.37, 
0.24; p=0.678)  
-0.07 (-0.38, 
0.24; p=0.655)  
 
 
